Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 3;17(10):3281-3287.
doi: 10.1080/21645515.2021.1943988. Epub 2021 Jun 25.

COVID-19 vaccine development from the perspective of cancer patients

Yang He  1 , Yi Ding  2 , Bo Cao  1 , Yi Huang  1 , Xiao Wang  3
Affiliations
Review

COVID-19 vaccine development from the perspective of cancer patients

Yang He et al. Hum Vaccin Immunother. .

Abstract

Currently, many companies around the world are actively developing COVID-19 vaccines. Fourteen vaccines with reliable safety and effectiveness are being successfully distributed to the public. However, there is no specific clinical trial data of the vaccines currently on the market on cancer patients at various stages, so the safety and effectiveness on cancer patients is unknown. This mini-review aims to discuss the impact of COVID-19 on cancer patients, and the urgent need of COVID-19 vaccines for cancer patients. In this review, we described the current status of the COVID-19 vaccine usages in cancer patients, as well as discussed potential problems in the use of vaccine. In addition, we included an original survey of the acceptance of the COVID-19 vaccines in 209 cancer patients and their family members. COVID-19 vaccine can provide cancer patients with social and medical benefits; therefore, clinical trials of vaccines on cancer patients are in great need.

Keywords: COVID-19; COVID-19 vaccine; Cancer patients; SARS-CoV-2; clinical trials; immunosuppression.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Scatter plot of COVID-19–related CFRs from series comparing rates from patients with cancer (blue dots) with patients without cancer (red dots)
See this image and copyright information in PMC

References

    1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–37. doi:10.1016/S1470-2045(20)30096-6. - DOI - PMC - PubMed
    1. Dooling K, McClung N, Chamberland M, Marin M, Wallace M, Bell BP, Lee GM, Talbot HK, Romero JR, Oliver SE, et al. The Advisory Committee on Immunization Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1857–59. doi:10.15585/mmwr.mm6949e1. - DOI - PMC - PubMed
    1. International Agency for Research on Cancer . Global Cancer Observatory.
    1. Nabioullin R, Sone S, Mizuno K, Yano S, Nishioka Y, Haku T, Ogura T.. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukoc Biol. 1994;55(4):437–42. doi:10.1002/jlb.55.4.437. - DOI - PubMed
    1. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–91. doi:10.1158/2159-8290.CD-20-0422. - DOI - PMC - PubMed